Perhaps you think it's impossible to score another 1,000% gain off this "tech titan" stock. Think again. An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
The “Tiregate” Scandal Can’t Derail This Growth Story…
by Robert Williams, Publisher
Thursday, September 24, 2009
The 35% tariff that President Obama just slapped on Chinese tire imports is not sitting well with the nation’s top brass, notably President Hu Jintao.
Chinese officials say that the tire decision represents a dangerous precedent toward protectionism and against the notion of free trade. They’re even threatening to “re-evaluate” their position on U.S. imports, like automobiles and poultry.
But Tiregate is more about the United Steelworkers union – the dominant force in U.S. tire plants – than anything else. The union is a pivotal ally in Obama’s fight on healthcare reform.
As such, I expect the spat to resolve itself at the upcoming G-20 summit in Pittsburgh. So don’t let this tit-for-tat derail your long-term investment outlook on China.
The rise of the middle class, predicated on steadily increasing income levels, will continue to serve as China’s growth catalyst.
Add in the fact that the Chinese economy is likely to grow by 8.9% next year – sharper than the 8% growth projected by the Asian Development Bank in March – and the country’s long-term investment appeal remains airtight. (Read Louis Basenese’s short-term China outlook here.)
Our analysts are tracking the region. Stay tuned for the best ways to play the next phase of China’s growth.
- An Australian Dollar Play on China’s Growth
- Jim Rogers: China Still a Buy
- China Overtakes Germany – Economically
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
In addition to once being a full-time trader of equities and equity derivatives, Robert Williams has also served as the lead financial analyst for a Forbes top-50 private corporation and an analyst for the endowment of a major academic institution.
Investment U RSS Feed